Targeting Traf6 Reverses Bone Loss by Rebalancing Inflammation in Aging Stem Cells

Age-related osteoporosis (senile osteoporosis, SOP) is driven in part by the progressive decline in osteogenic capacity of bone marrow stromal stem cells (BMSCs) as they undergo inflammatory senescence. Despite the known roles of oxidative stress and inflammasome activation in this process, the upstream molecular switch coordinating these events in aging BMSCs had not been clearly defined. This study systematically investigated whether Traf6, a key adaptor protein in innate immune signaling, orchestrates the Nrf2/Nlrp3 signaling axis to drive inflammatory senescence and bone loss.

Using high-throughput transcriptomic sequencing, the researchers compared primary BMSCs isolated from 18-month-old (aged) and young mice. Aged BMSCs showed significant enrichment of anti-inflammatory, antioxidant, and immune-related gene sets—paradoxically reflecting a compensatory stress response—alongside markedly elevated transcript levels of pro-inflammatory factors including TNF-α, IL-1β, IL-6, and Nlrp3. Protein-level analysis confirmed upregulation of Traf6 and Nlrp3 and downregulation of Nrf2 in senescent BMSCs, along with elevated senescence markers p16, p21, and p53, and reduced expression of osteogenic transcription factors Runx2 and Osterix.

In vitro, lentiviral shRNA knockdown of Traf6 in aged BMSCs suppressed NF-κB (p65) and MAPK (ERK, JNK, p38) pathway phosphorylation, rescued Nrf2 expression, and reduced Nlrp3 inflammasome assembly and downstream cytokine release (IL-1β, IL-18). Senescence markers decreased and osteogenic differentiation—assessed by ALP activity, Alizarin Red staining, and osteogenic protein expression—was significantly improved. These effects were partially reversed by the Nrf2 inhibitor ML385, confirming that Nrf2 acts as an intermediary through which Traf6 controls inflammasome activity and cellular aging.

In vivo experiments in aging mice receiving intramedullary lentiviral Traf6 knockdown demonstrated meaningful skeletal benefits. Micro-CT morphological analysis revealed increased trabecular bone volume and improved bone microarchitecture. Calcein double-labeling showed accelerated calcium deposition rates indicative of enhanced new bone formation. Immunohistochemistry confirmed reduced Nlrp3 and inflammatory cytokine expression in bone tissue, and serum ELISA showed decreased MDA (a marker of oxidative stress) alongside favorable shifts in bone metabolism indices.

Collectively, these findings establish a coherent signaling hierarchy: aging-associated upregulation of Traf6 activates NF-κB and MAPK cascades while suppressing Nrf2-mediated antioxidant defense, ultimately enabling Nlrp3 inflammasome assembly and a self-reinforcing cycle of inflammatory senescence that depletes the osteogenic capacity of BMSCs. Targeting Traf6 pharmacologically or genetically may represent a viable strategy to interrupt this cycle and slow the progression of senile osteoporosis.